Materials • Major Chemicals
$35.40 ▼ -0.39
(-1.09%)
MKT CAP: $8.59B • VOL: 2.62M
52W L $23 52W H $49
ESI // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $2.55B | $2.46B | $2.33B |
| YoY Revenue Growth % | +3.8% | +5.3% | — |
| Gross Profit | $1.07B | $1.04B | $1.03B |
| Gross Margin % | 42.0% | 42.2% | 44.0% |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | $342.2M | $343.9M | $173.6M |
| Operating Margin % | 13.4% | 14.0% | 7.4% |
| Net Income (GAAP) | $190.8M | $244.2M | $118.1M |
| EBITDA (Normalized) | $392.0M | $398.6M | $257.6M |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | $213.7M | $273.5M | $132.3M |
| Capital Expenditures (CapEx) | $62.2M | $68.4M | $105.0M |
| Free Cash Flow (FCF) | $151.5M | $205.1M | $27.3M |
| FCF Margin % | 5.9% | 8.3% | 1.2% |
| Return on Invested Capital (ROIC %) | 8.6% | 8.7% | 4.8% |
| Cash & Short-Term Equivalents | $626.5M | $359.4M | $519.6M |
| Total Debt (Short + Long Term) | $1.09B | $1.11B | $1.11B |
| Total Stockholders' Equity | $2.67B | $2.38B | $2.27B |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR ESI.